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Abstract
High-grade gliomas (HGG) are the most frequent primary central nervous system tumors; treatment of HCGs
includes surgery and post-operative conformal radiotherapy associated with temozolomide (TMZ or
procarbazine/lomustine/vincristine [PCV], specifically in patients with anaplastic oligodendrogliomas or
anaplastic oligoastrocytomas). However, recurrence is common. Re-irradiation has been utilized in this
setting for years and remains a feasible option, although there is always a concern regarding toxicity.
Modern high-precision conformal techniques, including stereotactic radiosurgery (SRS), could improve the
therapeutic ratio by delivering high biologically equivalent doses while reducing high-dose radiotherapy (RT)
to normal brain tissue. In this paper, we present the results obtained after prolonged follow-up in patients
who underwent SRS as a treatment for recurrent high-grade gliomas at San Francisco Hospital in Madrid,
Spain
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Introduction
High-grade gliomas (HGG) are the most frequent malignant primary central nervous system tumors in
adults, accounting for more than 20% of all primary brain neoplasms [1]. Surgery and post-operative
conformal radiotherapy (RT) associated with temozolomide (TMZ or procarbazine/lomustine/vincristine
[PCV], specifically in patients with anaplastic oligodendrogliomas or anaplastic oligoastrocytomas) have
become the cornerstone of therapeutic approaches. However, despite recent advances in treatment options,
local recurrence continues to be a common event.
The first challenge is the differential diagnoses between glioma recurrence and radiation necrosis, which is
crucial since the two entities have different treatment approaches and prognosis. Computed tomography
(CT) and magnetic resonance imaging (MRI) suffer from significant limitations in this setting [2]. Depending
on the clinical follow-up to make the distinction between radionecrosis and recurrence is a common
practice; however, this raises concerns, because in more than 30% of patients, radiation necrosis presents
itself as swelling or as a mass which results in clinical deterioration, requiring resection. Once recurrence is
confirmed or suspected, surgical resection is often the first option to alleviate symptoms, followed by
salvage systemic treatment or/and reirradiation [3]. Total tumor surgical resection can be difficult and
almost impossible to achieve due to the extensive parenchymal infiltration, the anatomical location, and
most importantly, the patient's own decision-making process regarding the willingness to undertake risks of
resection in the context of short survival expectation. Moreover, this aggressive strategy usually achieves
modest and transient results and should be reserved to a very specific subgroup of patients [3-4]. Concerning
systemic treatment, available regimens are often limited by patients’ poor condition, tumor resistance, poor
blood-brain barrier penetration, and significantly compromised overall patient functional status. Re-
challenging with TMZ or switching to a non-conventional TMZ regimen (for example, metronomic TMZ) has
become a common strategy [5]. More recently, several targeted therapies have been introduced in clinical
practice and investigated in clinical trials with uncertain results concerning safety, with no clear evidence of
benefit; antiangiogenic therapy with bevacizumab improves progression-free survival, without a significant
benefit in overall survival improvement [2,6].
Re-irradiation has been utilized in this setting for years and remains a feasible option, although there is
always the concern of a relatively high risk of toxicity [7-12]. Modern high-precision conformal techniques,
including stereotactic radiosurgery (SRS), have the power to improve the therapeutic ratio by delivering high
biologically equivalent doses while reducing high-dose RT to normal brain tissues [7]. In this paper, we
present the results obtained after prolonged follow-up in patients who underwent SRS as a treatment for
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recurrent high-grade gliomas at the Neurosurgery department at San Francisco Hospital in Madrid, Spain.
Materials And Methods
A total of 50 patients with recurrent HGGs (Grade III and IV) were retrospectively reviewed after being
treated with SRS at the Department of Neurosurgery in the San Francisco Hospital, Madrid, Spain from
January 1992 to December 2014. There were 36 men (72%) and 14 women (28%). The entire study
population had received surgery and adjuvant radiotherapy as the first course of treatment. Surgery was
performed on one patient, and in 23 patients (46%), only a biopsy was performed. Glioblastoma multiforme
was the diagnosis of 48% of the patients, while 40% had anaplastic astrocytomas and 12% had anaplastic
oligodendrogliomas. Most of the patients received systemic treatment (72%), TMZ being the most frequently
used drug (58%). At recurrence, patients presented behavior disturbances (48%), motor deficits (46%),































TABLE 1: Patient characteristics
The mean age of the whole group was 51.5 years (21-81 years). With regard to radiation treatment, the mean
delivered dose was 59.5 Gy (range: 40-76 Gy), and three patients received intraoperative radiation boost
(IORT) with doses varying from 6 to 12.5 Gy, according to the institutional protocol at that time [8]. The
mean interval between first treatment and recurrence was 23.2 months (range: 1 to 196 months), with this
interval being shorter in glioblastoma patients (mean: 13.5 months, range: 1-60 months) and larger in
oligodendroglioma patients (mean: 54.7 months, range: 9-196 months). The mean follow-up was 55.5
months (range: 11-357 months). Response assessment in neuro-oncology criteria (RANO) criteria has been
used to evaluate the imagenologic recurrence.
Since it is a broad retrospective series, the state of methylation (methylguanine DNA methyltransferase;
MGMT) or isocitrate dehydrogenase (IDH) in the treatment regimen is not taken into account and has not
been collected in several of the cases.
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Procedures
In all cases, SRS was carried out using a linear accelerator with a high-precision positioning system and
mechanical fixation of the tertiary collimator (SRS 200; University of Florida, Gainesville, FL), with 6-MV
photons. To locate the lesion, MRI was performed after which the stereotactic frame was placed under local
anesthesia for the planning CT phase. An image fusion program was used to fuse imaging datasets and
delimit the target volume. During the study period, different treatment planning systems were utilized.
Three-dimensional treatment planning was made in all cases, using different planning units (Philips SRS
200 [Philips, Madison, WI], Brain Lab [Brain-Lab, Feldkirchen, Germany], Plato-Nucletron [Nucletron,
Veenendaal, Netherlands], and ERGO-3D Line [3DLine Medical Systems, Milan, Italy]) during the period of
the study.
Dose planning was performed to cover target only the MRI enhancing tumor as conformational as possible.
Dose prescription took into consideration the following variables: previous doses delivered during the first
course of treatment, the interval between treatment and recurrence and proximity to critical structures,
such as the optic nerve, optic chiasma, or brainstem, and the clinical situation of the patient. A median dose
of 14 Gy (range: 8-20 Gy) was prescribed to the 90% (range: 50% to 100%) mean isodose surface. After SRS,
all patients were subjected to receive prophylactic treatment with dexamethasone and were observed in the
hospital for 24 hours to prevent any early complications. Tumor size before and after SRS was assessed by
measuring the contrast-enhanced margins in the three standard MRI dimensions. A follow-up MRI, with and
without gadolinium enhancement, was carried out after six and 12 months and yearly thereafter. MRI
protocols have evolved over the period of the study, along with the evolutionary implementation of MRI
technology, as did radiosurgically induced change interpretation.
Statistical analysis
The median survival was the survival defined as the time from the procedure (SRS) until the onset of clinical
progression or death. All eligible cases were included in the survival analysis. The estimation of the
cumulative proportion surviving was based on Kaplan-Meier procedures. To analyze factors correlating with
survival, the following parameters were assessed: age (50 years vs. >50 years), sex, and histology
(oligodendroglioma vs. anaplastic astrocytoma vs. glioblastoma). SPSS version 12.0 (SPSS Inc., Chicago, IL)
was used to analyze the results.
Results
The median overall survival (OS) of the whole group was 11 months (95% CI: 7.3 to 14.6 months). Around
half of the patients died by the end of the first year after radiosurgery (50.9%), and 17% were alive by the end
of the third year. Following SRS, 29 of our patients received adjuvant systemic chemotherapy, as per the
medical oncologist’s preference order following SRS.
There were no differences in median survival when comparing male to female patients by gender. Patients
under the age of 50 years showed no differences in OS when compared to their older counterparts, although
a tendency to an improved OS was noted in the younger population. 
When considering the histological type as expected, we observed significant better median survival in
anaplastic oligodendrogliomas (median survival: 91 months), anaplastic astrocytomas (median survival: 12
months; 95% CI: 7.9 to 16 months), and glioblastomas (median survival: 8 months; 95% CI: 4.1 to 11.8
months).
During the follow-up, six patients did not present toxicity following SRS, while 44 patients (88%) presented
toxicities: grade I (Radiation Therapy Oncology Group; RTOG): 21 patients (asymptomatic edema in
neuroimages that didn`t require treatment), grade II: 16 patients (asymptomatic edema that required short-
course corticosteroid use <1 month), and grade III: seven patients (symptomatic brain edema that required
prolonged use of corticosteroids).
Discussion
The standards of care for patients with recurrent glioblastoma are not well defined, and clinical decision-
making is often based on previous treatments, age, Karnofsky performance score (KPS), and patterns of
relapse [3-4].
Re-irradiation, for recurrent HGG, remains a controversial treatment option [13-15].
Likewise, surgery has limited applicability, and finally, systemic therapy, if utilized alone, does not provide
sufficient local control. RT has evolved to deliver higher tumor doses and reduce high-dose treatment to
normal tissue around the tumor. Median survival, following recurrence, has been described to be around 25
to 30 weeks in patients with glioblastoma and between 39 to 47 weeks in patients with grade III tumors [9].
In this study, a median progression-free survival (PFS) of almost 40 months and a median OS of 41.1 months
was observed, with half of the patients being alive at the end of the first year. These positive results may be
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explained, in part, because oligodendrogliomas are tumors that usually present a better prognosis in
comparison to anaplastic astrocytomas or glioblastomas.
On the other hand, the dose/rate effect, as well as the high single dose, improves the effectiveness of
radiotherapy. Based on our research and previous articles, it is clear that dose intensification is reflected
clinically in an increase in local control. In our series, this is prolonged up to 26 months in patients with
glioblastomas.
Regarding the high recurrence rate of HGGs, surgery remains the first option, but not all patients can be
treated surgically and in many cases, we have deep tumors. Reirradiation is a good option in this group of
patients, and radiosurgery has an advantage, in this sense, because it has the power to increase the dose of
radiation with high precision to a determined volume in a single treatment session (or hypofractionation)
when compared to conventional radiotherapy [15]. The dose gradient outside the white volume allows the
preservation of surrounding critical organs. Tsao performed a systematic review in 2005, where there was
insufficient evidence to make recommendations on the use of radiosurgery in the treatment of recurrent
disease [10]. However, to date, there is increasing evidence to clarify this question. In our study, the median
survival of 26 months in patients with glioblastoma was obtained, which is superior compared to similar
series of reirradiation with IMRT, even with the use of biological agents where survival was observed 9
months after the second treatment [3-6]. It is also superior compared to the series of the patients treated
with chemotherapy alone, where the reported survival rate was between 7 and 11 months and compared to
series where only radiosurgery was used, with reported results between 10.9 to 32 months of OS [13-20]. The
survival rates with radiosurgery observed in our series were 50.96% at one year, 17% at two years, and 6.22%
at five years, which is better than a similar study using rescued radiosurgery in single or multiple sessions, in
high gliomas, using a robotic accelerator [19].
Our patient complications are similar to those reported in the literature [21-22]. In our series, only one
patient needed surgical treatment. Variables such as KPS, initial resection, and non-multifocality may help
in the selection of patients who would benefit from local treatments such as radiosurgery, but independently,
all histological varieties of high-grade gliomas benefit from this treatment strategy [23-24].
One of the main factors in determining the dose of irradiation is the ability of brain tissue to recover from
sublethal damage, which is directly related to the effective biological dose of the first radiotherapy treatment
and, as well, to the interval between the first treatment and radiosurgery. One study suggests that the use of
extended fields, due to the infiltrative nature of the tumor, results in increased local control in small tumors.
Nonetheless, it shows no difference in Simpsons grade (SG) when compared with standard radiosurgery;
hence, we strongly believe that it is not necessary and SRS can protect better the normal tissues around [25].
Our study has some limitations. One of them is that it is a retrospective series. However, several similar
studies have shown a benefit in the group of patients who are candidates for radiosurgery [12,26-30]. Even
with this limitation, our results, in general, had better outcomes when compared to reports on previous
studies, as toxicities were scarce and delaying survival, after relapse.
Conclusions
In our study, patients with recurrent high-grade gliomas benefit from re-irradiation, with half of the
patients still surviving at the end of the first year. These positive results may be explained, in part, by the
presence of grade 3 oligodendrogliomas in our series. These results are comparable with other centers'
experience and they support the efficacy and safety of re-irradiation in this setting. Results are better in our
series if radiosurgery is used in grade 3 gliomas compared to grade 4 gliomas.
In conclusion, radiosurgery should be taken into account for the rescue of patients with recurrent high-
grade gliomas. However, further studies are needed to define possible subgroups with greater benefits.
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